Membrane-covered Express2TM Monorail® stents composed of chitosan (CH) blended with polyethylene oxide (PEO) in 70:30% wt (CH-PEO) were coated with a monolayer of hyaluronic acid (HA). This significantly improved the resistance to platelet adhesion and demonstrated excellent mechanical properties, resisting the harsh conditions during stent crimping and subsequent inflation. CH-PEO/HA membrane was then combined with a paclitaxel (Pac) delivery system via three different approaches for comparison of release profiles of Pac. The activity of Pac in these systems was confirmed since its presence in the membrane significantly decreased cell viability of U937 macrophages. Presented results are promising for applications requiring different release patterns of hydrophobic drugs.
Bibliographical noteFunding Information:
The authors wish to thank the Canadian Institutes for Health Research (CIHR) - Regenerative Medicine & Nanomedicine grant (CIHR Training Grant) and Fonds Québécois de Recherche sur la Nature et les Technologies (FQRNT)-Regroupment Stratégique for supporting this work.
The authors wish to thank the Canadian Institutes for Health Research (CIHR)-Regenerative Medicine & Nanomedicine grant (CIHR Training Grant) and Fonds Qu?b?cois de Recherche sur la Nature et les Technologies (FQRNT)-Regroupment Strat?gique for supporting this work.
© 2008 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland.
- Controlled drug release
- Hyaluronic acid
- Polyethylene oxide